Semaglutide

Name: Semaglutide
Brand: LyoPep

Lipidated GLP-1 analog · analytical and metabolic research reagent

≥ 99.0% · target, verify batch COACAS 910463-68-2RUO

Batch COA

MOQ1 kit (10 vials) per SKU

Supplied form31-residue peptide (GLP-1 receptor agonist analog, fatty-acid acylated)

Lead time10–18 days

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research uses include GLP-1 receptor pharmacology, analytical method development, impurity characterization and comparative metabolic-pathway studies
Clinical outcomes reported for approved finished products are literature context, not performance claims for this RUO lot.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 910463-68-2
Formula: C₁₈₇H₂₉₁N₄₅O₅₉
Molecular weight: 4113.6 g/mol
Appearance: White lyophilized powder
Purity: ≥ 99.0% · target, verify batch COA
Storage: Store and ship according to the released-lot COA, SDS and stability statement for the exact supplied form. Storage conditions for branded pens or tablets do not define stability of a bulk peptide, lyophilizate or laboratory solution.
MOQ: 1 kit (10 vials) per SKU
Lead time: 10–18 days

PubChem CID 56843331

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Follow the storage condition stated on the batch COA or label from receipt onward.

Research context

What researchers study about Semaglutide

Semaglutide is a lipidated 31-residue GLP-1 receptor agonist analog and the active ingredient in several named FDA-approved finished medicines. Those approvals and clinical data apply to the respective finished products, formulations and labelled uses. The material described on this page is a separate RUO bulk reagent and is not established as sterile, bioequivalent or suitable for administration.

The current US label describes product-specific uses for named finished injections and tablets in weight management and cardiovascular risk reduction, and an accelerated-approval MASH indication for WEGOVY injection
For this RUO reagent, relevant laboratory topics include receptor pharmacology, analytical characterization, impurities and comparative peptide research; no therapeutic indication is claimed.

Mechanism context

The question the literature is testing

Semaglutide is a GLP-1 receptor agonist analog with an Aib substitution that reduces DPP-4 cleavage, a Lys-linked C18 fatty-diacid moiety that promotes albumin binding, and a Lys-to-Arg substitution that controls the acylation site. In approved finished products, GLP-1 receptor activation affects glucose-dependent insulin secretion, glucagon secretion, gastric emptying and appetite. These pharmacology data do not establish formulation performance or clinical equivalence of an RUO bulk lot.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context

Research areaMetabolic and incretin research

Routes reported in sources

SubcutaneousOral

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

This RUO bulk material is not an approved finished drug and is not established as sterile, bioequivalent or suitable for human or veterinary administration
FDA states that unapproved products sold falsely as research material for direct human use may be of unknown quality and harmful, and that semaglutide sodium and acetate are different active ingredients from the semaglutide used in approved drugs
Clinical safety information for branded products must not be used to qualify this lot.

Interactions reported in the literature

Finished-product labels describe clinically relevant interactions and precautions
They are not use instructions for this bulk reagent; laboratory mixtures require method-specific compatibility and interference assessment.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Batch documentation

Semaglutide batch COAs

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

2 mg
5 mg
10 mg
15 mg
20 mg
30 mg
50 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

Representative records, refreshed periodically

Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.

Third-party reports, added progressively

Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.

Help reviewing your COA

Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

Qualify the exact modified sequence, terminal state, lipid linker, supplied form and counterions
Review intact mass, a defined chromatographic method and impurity profile, peptide-content or assay basis, water, residual solvents, aggregates where relevant and released-lot storage
HPLC area purity alone does not establish content, identity, sterility or equivalence to an approved medicine.

Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

SEMA22 mg10 vials

SEMA55 mg10 vials

SEMA1010 mg10 vials

SEMA1515 mg10 vials

SEMA2020 mg10 vials

SEMA3030 mg10 vials

SEMA5050 mg10 vials

Other format

Also available as a nasal spray (US stock)

Black 10 mL nasal spray bottle with a clear cap — 10 mL nasal spray bottle

Besides lyophilized vials, Semaglutide is also supplied as a nasal spray solution, shipped from our US stock.

Strengths: 2 mg · 5 mg · 10 mg · 15 mg · 20 mg · 30 mg
Bottle sizes: 10 mL or 20 mL
Minimum order: 10 bottles per strength and bottle size
Ships from: Our US stock

Handling

Plan storage before the parcel arrives

Store and ship according to the released-lot COA, SDS and stability statement for the exact supplied form. Storage conditions for branded pens or tablets do not define stability of a bulk peptide, lyophilizate or laboratory solution.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

What if my own lab test shows the product is out of specification?+

Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

How should material be stored after delivery?+

Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

The current FDA prescribing information revised June 2026 documents WEGOVY injection and tablets as approved finished products. The tablet NDA was approved December 22, 2025; the label assigns weight-management and cardiovascular-risk indications to the tablets, while the accelerated-approval MASH indication applies to the injection. This label context does not qualify an independently supplied RUO bulk lot.
Wharton S, et al. N Engl J Med. 2025;393:1077-1087. PMID 40934115, DOI 10.1056/NEJMoa2500969, OASIS 4. In 307 randomized adults, oral semaglutide 25 mg or placebo was studied for 64 weeks. The treatment-policy estimand was -13.6% versus -2.2% body-weight change; the trial-product estimand was approximately -16.6% versus -2.7%. These are different analyses of one finished-product trial, not conflicting values or evidence for this RUO lot.
Lincoff AM, et al. N Engl J Med. 2023;389:2221-2232. PMID 37952131, DOI 10.1056/NEJMoa2307563, SELECT. Among 17,604 participants with established cardiovascular disease and overweight or obesity but without diabetes, the primary event hazard ratio was 0.80 (95% CI 0.72-0.90) over a mean 39.8-month follow-up. Trial-product discontinuation due to adverse events was 16.6% with semaglutide and 8.2% with placebo, mainly because of gastrointestinal disorders.
Garvey WT, et al. Nat Med. 2022;28:2083-2091. PMID 36216945, DOI 10.1038/s41591-022-02026-4, STEP 5. In 304 randomized participants, mean body-weight change at 104 weeks was -15.2% with semaglutide and -2.6% with placebo; gastrointestinal adverse events were reported in 82.2% and 53.9%, respectively. The results describe a named clinical-trial regimen, not bulk-reagent performance.
FDA proposed on April 30, 2026 not to include semaglutide, tirzepatide or liraglutide on the 503B Bulks List after finding insufficient evidence of clinical need for outsourcing facilities to compound them from bulk substances. A Federal Register notice extended the public-comment deadline to July 30, 2026. A proposal and comment period are not a final listing decision, and neither establishes approval or suitability of this RUO lot.

01
Once-Weekly Semaglutide in Adults with Overweight or Obesity
New England Journal of Medicine · 2021 · peer-reviewed original research (randomized controlled trial)
Open source
02
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
New England Journal of Medicine · 2025 · peer-reviewed original research (randomized controlled trial)
Open source
03
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
New England Journal of Medicine · 2023 · peer-reviewed original research (randomized controlled trial)
Open source
04
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
New England Journal of Medicine · 2016 · peer-reviewed original research (randomized controlled trial)
Open source
05
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
New England Journal of Medicine · 2019 · peer-reviewed original research (randomized controlled trial)
Open source
06
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis
New England Journal of Medicine · 2025 · peer-reviewed original research (randomized controlled trial, planned interim analysis)
Open source
07
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Nature Medicine · 2024 · peer-reviewed original research (secondary/subgroup analysis of RCT)
Open source
08
Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review
International Journal of Molecular Sciences · 2024 · systematic literature review
Open source

Product FAQ

Questions buyers ask about Semaglutide

What are Semaglutide's reference identity values?+

The commonly cited free-compound reference is CAS 910463-68-2, PubChem CID 56843331, formula C₁₈₇H₂₉₁N₄₅O₅₉ and average molecular weight about 4113.6 Da. Because the molecule is sequence- and linker-defined, the batch record should also identify the modified sequence, lipid linker, terminal state, supplied form and counterions.

What documentation should be agreed before qualifying a Semaglutide lot?+

Define the required COA before ordering: exact modified sequence and supplied form, intact mass, chromatographic method and impurity profile, peptide-content or assay basis, water, residual solvents, counterions and storage conditions supported for the released lot. Request orthogonal identity, aggregate, endotoxin, bioburden, sterility or solution-stability testing only when required by the intended laboratory workflow and confirm availability in writing.

Evidence before order

Buyer intelligence

Ready for review

Request a usable quote

Include fill, quantity, target purity/content, required methods, destination and timing.

B2B response target: 24 hours
1 kit MOQ per SKU
Batch COA: HPLC, MS, endotoxin, fill

Research Use Only. Human-use requests are not accepted.

Recent activity window

Recent confirmed orders including Semaglutide

Recent Confirmed Orders18 · Last 30 days

United Arab Emirates5.7 g2026-11-09

Tirzepatide 120 mg · Semaglutide 20 mg · ARA 290 (Cibinetide) 16 mg · GLOW (BPC+GHK-Cu+TB) 70 mg

United States6.9 g2026-11-04

Tirzepatide 100 mg · CJC-1295 without DAC 10 mg · TB-500 10 mg · CJC-1295 + Ipamorelin 10 mg · Semaglutide 30 mg · IGF-1 LR3 1000 mcg · Sterile Water 3 mL

United States7.5 g2026-11-04

Semaglutide 50 mg · Tesa+IP5 15 mg · PT-141 10 mg · BPC-157 10 mg

Kenya60 mg2026-11-03

Semaglutide 2 mg

Canada90 mg2026-11-02

Semaglutide 2 mg · GHRP-2 5 mg · Bacteriostatic Water 10 ml

Türkiye4.3 g2026-11-02

Glutathione 400 mg · MOTS-c (Human) 10 mg · Semaglutide 2 mg · CagriSema 5 mg · CJC-1295 + Ipamorelin 10 mg

United States3.7 g2026-10-28

Semaglutide 50 mg · CJC-1295 + Ipamorelin 10 mg · BPC-157 10 mg · Menotropins (HMG) 75 IU nominal fill; confirm FSH and LH activities on the batch COA

United States470 mg2026-10-27

Tirzepatide 40 mg · Semaglutide 2 mg · IGF-1 LR3 1000 mcg · TB-500 2 mg · Bacteriostatic Water 10 ml

United States1 g2026-10-25

Semaglutide 20 mg · Melanotan II 10 mg · ARA 290 (Cibinetide) 10 mg

United Kingdom570 mg2026-10-24

GHK-Cu 50 mg · Kisspeptin-10 5 mg · Semaglutide 2 mg

United Kingdom26 g2026-10-23

Tirzepatide 120 mg · PE-22-28 10 mg · BPC-157 + TB-500 (Wolverine Stack) 30 mg · Semaglutide 50 mg · MOTS-c (Human) 40 mg · CJC-1295 without DAC 10 mg

Australia540 mg2026-10-23

GHK-Cu 50 mg · Semaglutide 2 mg · Cagrilintide 2 mg · EPO 3,000 IU · Bacteriostatic Water 3 ml

Australia23 g2026-10-22

Retatrutide 60 mg · Sermorelin 10 mg · Hexarelin Acetate 5 mg · Semaglutide 50 mg · Tesa+IP5 15 mg · BPC-157 10 mg · Melanotan II 10 mg · Kisspeptin-10 10 mg · TB500 Fragment (Frag 17-23) 10 mg · CJC-1295 without DAC 10 mg · MOTS-c (Human) 40 mg

United States25.5 g2026-10-21

GHK-Cu 100 mg · Semaglutide 50 mg · Survodutide 10 mg · Sermorelin 10 mg · Hexarelin Acetate 5 mg · AHK-Cu 100 mg · Bacteriostatic Water 3 ml

Peru60 mg2026-10-18

Semaglutide 2 mg · Bacteriostatic Water 3 ml

France2.3 g2026-10-17

KLOW (GHK-Cu + BPC-157 + TB-500 + KPV) 80 mg · CJC-1295 + Ipamorelin 10 mg · Semaglutide 20 mg

United States200 mg2026-10-15

Semaglutide 5 mg · Melanotan II 10 mg

Canada950 mg2026-10-14

Tirzepatide 80 mg · Semaglutide 5 mg · Epithalon 10 mg · Menotropins (HMG) 75 IU nominal fill; confirm FSH and LH activities on the batch COA

Only a portion of all confirmed orders is shown here.

Semaglutide

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Semaglutide

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Semaglutide batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Also available as a nasal spray (US stock)

Plan storage before the parcel arrives

Terms to settle before the purchase order

Literature behind the research context

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review

Questions buyers ask about Semaglutide

Buyer intelligence

Compare adjacent molecules and documentation needs.

Tirzepatide

Retatrutide

Cagrilintide

Liraglutide